由于费用高、证据有限、病人和倡导者令人失望,国家保健服务机构拒绝例行提供新的脑癌新药物。 NHS denies routine access to new brain cancer drug due to cost and limited evidence, disappointing patients and advocates.

脑癌患者在国民保健制度决定不批准一种新药物用于常规用途后表示失望,尽管人们希望改进治疗方案,但以成本和有限的有效性证据为例,他们对此表示失望。 Patients with brain cancer have voiced disappointment after the NHS decided not to approve a new drug for routine use, citing cost and limited evidence of effectiveness despite hopes for improved treatment options. 这一决定影响到整个英格兰获得药物的机会,引起了病人和倡导团体的关切,他们认为,它本可以为生存前景有限的人提供一条生命线。 The decision, which affects access to the drug across England, has sparked concern among patients and advocacy groups who argue it could have offered a lifeline for those with limited survival prospects.